Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

Table 5 Patients with emerging mutations^a in patients with failure,^b by baseline Q80K polymorphism (ITT population)

n/N (%)	Phase 2/3 group (N = 125)	Phase 1 group (N = 16)
Failure	38	10
Sequencing data
Available^c	33/38	8/10
Not available	5/38	2/10
Emerging mutations at failure	27/33 (81.8)	7/8 (87.5)
Without Q80K at baseline	24/33 (72.7)	7/8 (87.5)
D168V	9/33 (27.3)	4/8 (50.0)
Q80L + R155K	2/33 (6.1)	0/8
D168E/V + F169I	1/33 (3.0)	0/8
Q80L + D168V	1/33 (3.0)	0/8
Q80L + I132L + R155K	1/33 (3.0)	0/8
Q80R	1/33 (3.0)	0/8
Q80R + D168E	1/33 (3.0)	0/8
Q80R + D168E/V	1/33 (3.0)	0/8
Q80R + R155K	1/33 (3.0)	0/8
R155K	1/33 (3.0)	0/8
R155K + D168A/N/T	1/33 (3.0)	0/8
R155K + D168E/V + I170V	1/33 (3.0)	0/8
R155K + N174 K	1/33 (3.0)	0/8
R155K + N174S	1/33 (3.0)	0/8
R155Q + D168V	1/33 (3.0)	0/8
D168A/V + I170V	0/33	1/8 (12.5)
Q80K	0/33	1/8 (12.5)
S122R + R155K	0/33	1/8 (12.5)
With Q80K at baseline	3/33 (9.1)	0/8
R155K	2/33 (6.1)	0/8
D168E	1/33 (3.0)	0/8
No emerging mutation at failure	6/33 (18.2)	1/8 (12.5)
Without Q80K at baseline	6/33 (18.2)	0/8
With Q80K at baseline	0/33	1/8 (12.5)

^aConsidering NS3 positions 36, 41, 43, 54, 55, 80, 107, 122, 132, 138, 155, 156, 158, 168, 169, 170, 174, and 175
^bFailures: all patients with failure
^cOnly patients with baseline and post-baseline sequencing data are considered
ITT intent-to-treat

ISSN: 1471-2334